sST2 is a promising biomarker in inflammation, atherosclerosis, and cardiovascular diseases. This study was done to investigate the association between serum sST2 and poor outcome in patients with TIA/ischaemic stroke.
A total of 430 patients included, the median sST2 was 17.72 ng/mL. A total of 19 and 38 patients experienced poor outcomes within 90 days and 1 year, respectively. Compared with the lowest sST2 tertile, hazard ratios (HRs)for the highest tertile were 5.14 for poor outcome within 90 days and 3.00 at 1 year after multivariate adjustments. Adding sST2 to a prediction model significantly improved risk stratification of poor outcome in TIA/ischaemic stroke, as observed by the continuous net reclassification improvement of 60.98% and integrated discrimination improvement of 2.63% at 90 days and the continuous net reclassification improvement of 41.68% at 1 year.
The study concluded that the increased serum sST2 levels in TIA/ischaemic stroke were associated with increased risks of poor outcome within 90 days and 1 year, suggesting that serum sST2 may be a potential long‐term prognostic biomarker for TIA/ischaemic stroke.